UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
February 9, 2007
Date of Report (Date of
earliest event reported)
Poniard Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Washington | | 0-16614 | | 91-1261311 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File No.) | | (IRS Employer
Identification No.) |
7000 Shoreline Court, Suite 270, South San Francisco, California 94080
(Address of principal executive offices) (Zip Code)
(650) 583 3774
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8 — Other Events
Item 8.01. Other Events.
On February 9, 2007, the Company announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) which, when declared effective by the SEC, will allow the Company from time to time to offer and sell up to $75 million aggregate amount of common stock, warrants or a combination thereof.
On February 13, 2007, the Company announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration (“FDA”) for an oral formulation of picoplatin. Following FDA review, the Company intends to initiate a Phase I clinical trial of oral picoplatin.
See press releases attached hereto as Exhibit 99.1 and 99.2 and incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 - - Press release dated February 9, 2007
99.2 — Press release dated February 13, 2007
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Poniard Pharmaceuticals, Inc. |
| | |
Dated: February 14, 2007 | By: | /s/ Anna L. Wight |
| | Name: Anna L. Wight |
| | Title: Vice President, Legal |
| | |
2
EXHIBIT INDEX
Exhibit No. | | Description |
99.1 | | Press Release dated February 9, 2007 |
| | |
99.2 | | Press Release dated February 13, 2007 |
3
